- Forus raised $150 million in Series C funding, tripling its valuation to $3 billion in four months,
- Bain Capital Ventures led the round, and every existing institutional investor reinvested.
- The AI network now reaches patients in 85% of US residential ZIP codes across all 50 states.
Nearly a third of patients prescribed high-cost or complex medicines never take their first dose, according to Forus, and those who do often wait weeks or months to start.
The startup’s answer is an AI agent assigned to every single prescription, and investors are paying up for the idea: Forus has raised $150 million in Series C funding at a $3 billion valuation, tripling its worth within four months of its previous round.
Bain Capital Ventures led the round and has backed Forus since its seed stage. Every existing institutional investor reinvested, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel.
The raise pushes Forus’ total funding past $300 million, four months after it closed more than $160 million as Tandem, the name it carried before rebranding in May.
“We are putting the Forus platform in every doctor’s office in the country, so every disease is treated with the best medicine science can offer. Medicine is advancing faster than at any point in history, increasing the urgency to make sure those advances reach the people they’re meant for,” said Sahir Jaggi, the company’s founder and chief executive.
From prescription to treatment
Jaggi started the company in 2023 after roughly five years at Oscar Health, where he worked on healthcare strategy and patient experience. He studied biomedical engineering at Columbia University beforehand.
Tech Funding News reported in January that Tandem was closing in on unicorn status with a $100 million round led by Accel; the company has since blown past that mark twice over.
Forus connects doctors, pharmacies, payers, and biopharma companies into one network. Each prescription gets its own AI agent, which checks a patient’s medical history, insurance coverage, and financial circumstances, then works the paperwork itself: prior authorisations, financial assistance applications, pharmacy routing. The service costs neither providers nor patients anything.
That model now runs across all 50 states, reaching patients in 85% of the country’s residential ZIP codes. More than a third of providers in the company’s first specialty use the platform, and adoption is spreading ito other specialties Nine of the world’s 15 largest biopharma companies work with Forus, giving those firms visibility into where patients and doctors hit friction after a drug reaches the market.
“Forus is becoming how new medicine reaches people in America. We have backed the company since its seed, and in that time the largest companies in medicine have turned to it to bring their newest medicines to patients,” said Kevin Zhang, general partner at Bain Capital Ventures.
A crowded field
Healthcare AI investors have no shortage of places to put money right now. OpenEvidence, which gives doctors an AI-powered clinical search tool, raised $250 million at a $12 billion valuation in January. Devoted Health, which pairs Medicare Advantage coverage with its own care-coordination AI, was reportedly in talks for a new round at a $25 billion valuation in August. Both are chasing the clinical or insurance side of healthcare AI.
Forus is staking its claim on the gap in between, the stretch where a prescription sits after a doctor writes it and before a patient actually takes it.
Dr. Brinda Dixit, a rheumatologist at Virginia Rheumatology Clinic in Chesapeake, Virginia, said patients used to wait two or three months to start treatment. “With Forus, approvals for these medications come back in less than two days, and patients start treatment within a week or two,” she said.
The new capital will go toward expanding into more specialties and care settings, building out the AI agents’ capabilities, and growing the team. Whether Forus can keep tripling its valuation every few months without a Series D correction is the question that decides if this becomes a category winner or the next AI valuation that got ahead of itself.
